News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
282,108 Results
Type
Article (14929)
Company Profile (299)
Press Release (266874)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79844)
Career Advice (163)
Deals (13338)
Drug Delivery (39)
Drug Development (50708)
Employer Resources (31)
FDA (5844)
Job Trends (5170)
News (145103)
Policy (10073)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (21)
Adcomms (14)
Allergies (86)
Alliances (21763)
ALS (127)
Alzheimer's disease (1041)
Antibody-drug conjugate (ADC) (248)
Approvals (6043)
Artificial intelligence (269)
Autoimmune disease (124)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (103)
Biotechnology (230)
Bladder cancer (102)
Brain cancer (47)
Breast cancer (349)
Cancer (3188)
Cardiovascular disease (241)
Career advice (148)
Career pathing (8)
CAR-T (225)
CDC (5)
Cell therapy (580)
Cervical cancer (14)
Clinical research (43753)
Collaboration (1176)
Company closure (2)
Compensation (610)
Complete response letters (43)
COVID-19 (1102)
CRISPR (91)
C-suite (577)
Cystic fibrosis (112)
Data (4395)
Denatured (15)
Depression (96)
Diabetes (257)
Diagnostics (1387)
Digital health (13)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (198)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (220)
Earnings (31709)
Editorial (27)
Employer branding (4)
Employer resources (29)
Events (51766)
Executive appointments (631)
FDA (7623)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (997)
Gene editing (188)
Generative AI (22)
Gene therapy (498)
GLP-1 (508)
Government (1151)
Grass and pollen (3)
Guidances (166)
Healthcare (6615)
HIV (19)
Huntington's disease (44)
IgA nephropathy (75)
Immunology and inflammation (197)
Immuno-oncology (44)
Indications (75)
Infectious disease (1215)
Inflammatory bowel disease (160)
Inflation Reduction Act (10)
Influenza (42)
Intellectual property (171)
Interviews (18)
IPO (7347)
IRA (13)
Job creations (867)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (24)
Layoffs (244)
Leadership (10)
Legal (1401)
Liver cancer (41)
Longevity (11)
Lung cancer (429)
Lymphoma (254)
Machine learning (24)
Management (7)
Manufacturing (382)
MASH (133)
Medical device (2669)
Medtech (2678)
Mergers & acquisitions (6626)
Metabolic disorders (737)
Multiple sclerosis (107)
NASH (13)
Neurodegenerative disease (238)
Neuropsychiatric disorders (70)
Neuroscience (1984)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (867)
Now hiring (31)
Obesity (336)
Opinion (126)
Ovarian cancer (132)
Pain (103)
Pancreatic cancer (167)
Parkinson's disease (235)
Partnered (12)
Patents (313)
Patient recruitment (350)
Peanut (44)
People (26711)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15503)
Phase 2 (20330)
Phase 3 (12838)
Pipeline (3438)
Policy (92)
Postmarket research (853)
Preclinical (6546)
Press Release (30)
Prostate cancer (148)
Psychedelics (50)
Radiopharmaceuticals (242)
Rare diseases (667)
Real estate (1448)
Recruiting (12)
Regulatory (9953)
Reports (20)
Research institute (975)
Resumes & cover letters (19)
Rett syndrome (24)
RNA editing (21)
RSV (18)
Schizophrenia (125)
Series A (186)
Series B (140)
Service/supplier (1)
Sickle cell disease (79)
Special edition (19)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2007)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (345)
Venture capital (70)
Weight loss (174)
Women's health (27)
Worklife (2)
Date
Today (86)
Last 7 days (305)
Last 30 days (1275)
Last 365 days (17825)
2026 (2176)
2025 (18098)
2024 (20544)
2023 (22415)
2022 (26822)
2021 (27805)
2020 (23358)
2019 (16224)
2018 (11740)
2017 (13746)
2016 (11840)
2015 (14350)
2014 (10394)
2013 (7486)
2012 (7532)
2011 (7617)
2010 (7429)
Location
Africa (154)
Alabama (66)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18285)
Australia (3117)
California (7185)
Canada (1873)
China (786)
Colorado (250)
Connecticut (259)
Delaware (239)
Europe (39250)
Florida (920)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (400)
India (36)
Indiana (164)
Iowa (8)
Japan (231)
Kansas (81)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (746)
Massachusetts (5660)
Michigan (110)
Minnesota (252)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (33)
New Hampshire (21)
New Jersey (1670)
New Mexico (13)
New York (1787)
North Carolina (844)
North Dakota (6)
Northern California (3540)
Ohio (180)
Oklahoma (11)
Oregon (24)
Pennsylvania (1296)
Puerto Rico (9)
Rhode Island (26)
South America (215)
South Carolina (9)
Southern California (2851)
Tennessee (41)
Texas (927)
United States (23690)
Utah (98)
Virginia (140)
Washington D.C. (37)
Washington State (595)
West Virginia (1)
Wisconsin (47)
282,108 Results for "mozart therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Mozart Therapeutics Announces Oral Presentation on MTX-101 at the 2024 American Diabetes Association’s 84th Scientific Sessions
Mozart Therapeutics, a clinical stage biopharmaceutical company focused on the development of CD8 Treg modulators for the treatment of autoimmune diseases, today presented new preclinical data on the Company’s lead program, MTX-101.
June 21, 2024
·
2 min read
Drug Development
Mozart Therapeutics to Present Pre-clinical Data on KIR x ICOS CD8 Treg Modulator at Immunology 2024 Meeting
Mozart Therapeutics, the leading developer of CD8 Treg network modulators, today announce the release of new pre-clinical data for their second program, a KIR x ICOS bispecific antibody targeting CD8 regulatory T cells.
May 3, 2024
·
2 min read
Drug Development
Mozart Therapeutics Doses First Cohort of Participants in Phase 1a/b Clinical Trial of MTX-101, in Development for Treatment of Autoimmune Diseases
Mozart Therapeutics, a clinical stage biopharmaceutical company focused on the development of CD8 Treg modulators in autoimmune diseases, today announce the dosing of the first cohort of participants in the Company’s initial clinical study of MTX-101, a first-in-class CD8 Treg modulator and autoimmune checkpoint inhibitor.
June 17, 2024
·
2 min read
BioForest
Mozart Therapeutics Presents Non-clinical Data on Lead Program, MTX-101 for Treatment of Autoimmune Diseases, at Society of Toxicology Annual Meeting 2024
Mozart Therapeutics, the leading developer of CD8 Treg modulators for the treatment of autoimmune and inflammatory diseases, today announce new non-clinical data for MTX-101.
March 14, 2024
·
2 min read
Business
Mozart Therapeutics Expands Executive Leadership Team with Appointments of Dr. Jason Chien, Chief Medical Officer, and Russ Hawkinson, Chief Financial Officer
Mozart Therapeutics today announced the expansion of its executive leadership team with the appointments of Jason Chien , MD, as Chief Medical Officer, and Russ Hawkinson as Chief Financial Officer.
October 30, 2023
·
2 min read
BioForest
Mozart Therapeutics Presents Preclinical Data for MTX-101, a Novel Bispecific CD8 Treg Modulator for Treatment of Autoimmune Diseases, at American College of Rheumatology Convergence 2023
Mozart Therapeutics presented preclinical pharmacology and tolerability data for MTX-101,a CD8 Treg modulator at the annual meeting of the American College of Rheumatology being held at the San Diego Convention Center in San Diego.
November 13, 2023
·
2 min read
BioForest
Mozart Therapeutics Raises $25 Million in Expanded Series A Financing to Support Clinical Development of First-in-Class CD8 Treg Modulators for the Treatment of Autoimmune Diseases
Mozart Therapeutics today announced it has raised $25 million from new investors in a Series A extension, bringing the total raise to $80 million.
June 7, 2023
·
3 min read
Drug Development
Mozart Therapeutics Presents Preclinical Data for MTX-101, a Novel CD8 Treg Network Modulator for Treatment of Autoimmune Disease, at FOCIS 2023 Annual Meeting
Mozart Therapeutics today announced the presentation of preclinical pharmacologic and tolerability data for MTX-101, a bispecific autoimmune checkpoint inhibitor, at the Annual Meeting of the Federation of Clinical Immunology Societies.
June 21, 2023
·
1 min read
BioForest
Mozart Therapeutics Highlights Promising Preclinical Activity of Novel CD8 Treg Network Modulator for Treatment of Autoimmune Diseases in Presentations at IMMUNOLOGY™ 2023
Mozart Therapeutics today announced the presentation of data at the American Association of Immunologists (AAI) Annual Meeting demonstrating the potential of its lead therapeutic, a targeted, bispecific CD8 Treg modulator, as a new therapeutic treatment approach for autoimmune diseases.
May 15, 2023
·
2 min read
Business
Mozart Therapeutics Announces Appointment of Jan Beck as Chief Operating Officer
Mozart Therapeutics today announced the appointment of Jan Beck as Chief Operating Officer.
March 21, 2022
·
2 min read
1 of 28,211
Next
